engleski

Serum concentrations of Hsp60 and Hsp70 in patients with cerebral atherosclerosis

Previous studies suggest that heat shock proteins (Hsp) have a contributory role in atherosclerosis development. The intention of this study is to investigate serum concentrations of Hsp60 and Hsp70 in patients with cerebral atherosclerosis. A group of patients with cerebral atherosclerosis, evaluated by digital subtraction angiography, with >50% stenosis of cerebral artery (n=50) was compared to the control group (n=25) concerning serum concentrations of Hsp60 and Hsp70. Hsp60 and Hsp70 were assayed by commercially available ELISA kits (Stressgen, USA). Serum Hsp60 was detectable in 74% of subjects with concentrations ranging from 3.13 µg/l to 391.34 µg/l (mean, 33.96 ; median, 14.25 µg/l). There was no significant difference in Hsp60 levels in patients compared to controls. The high Hsp60 level group (above the median value) contained 61% cerebral stenosis patients, whereas the low Hsp60 group had 68% cerebral stenosis patients, without significant difference in proportions. Serum Hsp70 was detectable in 52% of subjects with concentrations ranging from 0.09 µg/l to 5.47 µg/l (mean, 0.424 ; median, 0.024 µg/l). There was no significant difference in Hsp70 levels in patients compared to controls. The high Hsp70 level group (above the median value) contained 55% cerebral stenosis patients, whereas the low Hsp70 group had 79% cerebral stenosis patients (p<0.05). There was no difference in serum Hsp60 and Hsp70 concentrations in the group of patients with cerebral atherosclerosis compared to the control group. Patients with cerebral atherosclerosis had greater prevalence of low Hsp70 serum levels. The deficiency in serum Hsp70 concentration could influence cerebral atherosclerosis development.

Hsp60; Hsp70; cerebral atherosclerosis

nije evidentirano